GE HealthCare Technologies Inc

Q2 performance beats expectations (orders strong; revenue solid): - Revenue: $5.3B, +3.5% organic YoY (in line with expectations). - Orders: +11.1% YoY organic (highest since the spin); book-to-bill: 1.15x. - Backlog: $23.9B, +$2.6B YoY and +$2.1B sequentially (record backlog). - Management said orders were broad-based and not driven by one-time items, with some contribution from ~6 enterprise accounts.

Segment mix: strong PDx, challenged PCS (key negative): - Advanced Imaging Solutions (AIS): Organic revenue +5% YoY, EBIT margin +90 bps YoY (volume/price up, inflation partly offset). - Pharmaceutical Diagnostics (PDx): Organic revenue +14.6% YoY; EBIT margin 29.6% (+30 bps YoY) driven by contrast media and U.S. radiopharma growth (disease-specific tracers; examples included Vizamyl and other tracers). - Patient Care Solutions (PCS): Organic revenue -13.5% YoY, EBIT negative due to operational fulfillment/supply issues; management says changes are underway to improve supply/manufacturing and expects sequential improvement in H2 (July started well). - PCS strategic review underway: management is conducting a comprehensive review of strategic options (including sale/transactions), explicitly still considering continued ownership.

Financials, margins, and cash flow (surprising but somewhat cushioned by tariff refunds): - Adjusted EBIT: $750M; margin 14.2% (-40 bps YoY). - EPS: Adjusted EPS $1.13 (+6.6% YoY) helped by $0.04 of tariff refunds and $0.02 from lower tax rate. - Free cash flow: $68M (includes $107M tariff refunds). - Margin headwinds called out: PCS challenge plus incremental inflation (memory chips, oil/freight, components). - Offset/positives: strong volume execution and early benefits from price/cost actions plus higher-margin new products.